Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 11/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 5/20 | 0.40 |
| ▸ | PTGER3 | P43115 | 5/20 | 0.40 |
| ▸ | PTGER2 | P43116 | 5/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 2/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4323200 | 0.93 | PTGER1 (0.50) | PTGER1SCN9APTGER4PTGER3PTGER2 | |
| SCHEMBL4327295 | 0.92 | PTGER1 (0.43) | PTGER1SCN9APTGER4PTGER3PTGER2 | |
| SCHEMBL4314140 | 0.91 | PTGER1 (0.41) | PTGER1SCN9APTGER4PTGER3PTGER2 | |
| SCHEMBL4320127 | 0.91 | PTGER1 (0.42) | PTGER1SCN9AFEN1AOC3DPP4 | |
| SCHEMBL4329018 | 0.87 | PTGER1 (0.47) | PTGER1SCN9APTGER4PTGER3PTGER2 | |
| SCHEMBL4320064 | 0.84 | PTGER1 (0.55) | PTGER1PTGER4PTGER3PTGER2CYP2C9 | |
| SCHEMBL4327329 | 0.84 | PTGER1 (0.47) | PTGER1SCN9ACYP2C9CYP3A4FEN1 | |
| SCHEMBL4320240 | 0.83 | PTGER1 (0.42) | PTGER1SCN9AFEN1AOC3 | |
| SCHEMBL4324627 | 0.82 | NPC1 (0.42) | SCN9ACYP2C9CYP3A4CYP2D6AOC3 | |
| SCHEMBL13754841 | 0.81 | SCN9A (0.52) | SCN9ACYP2C9CYP3A4CYP2D6FEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090074890-A1 | Substituted Triazoles as Sodium Channel Blockers | MERCK SHARP & DOHME CORP. | 2009-03-19 | — | — | US | disclosed |
| US-20090074890-A1 | Substituted Triazoles as Sodium Channel Blockers | MERCK SHARP & DOHME CORP. | 2009-03-19 | — | — | US | disclosed |
| US-7459475-B2 | Substituted triazoles as sodium channel blockers | MERCK & CO. INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-7459475-B2 | Substituted triazoles as sodium channel blockers | MERCK & CO. INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-20060020006-A1 | Substituted triazoles as sodium channel blockers | MERCK SHARP & DOHME LLC | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090074890-A1 | Substituted Triazoles as Sodium Channel Blockers | TRPV1, SCN3A, SCN5A | PTGER1 964/4885SCN9A 50/4885PTGER4 1065/4885 |
| US-20060020006-A1 | Substituted triazoles as sodium channel blockers | TRPV1, SCN3A, SCN5A | PTGER1 964/4885SCN9A 50/4885PTGER4 1062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.